Amjad Masad and Haya Odeh built Replit together from scratch. Can they defend its position as an industry juggernaut?
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options If you purchased or acquired ...
Replit CEO Amjad Masad said his company's office has become "more vibrant" since his software engineers started vibe coding.
A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune”) (NASDAQ: REPL). The lawsuit ...
After two rejections and layoffs that eliminated more than 200 jobs, Massachusetts biotech Replimune Group finally secured ...
XDA Developers on MSN
After a week in Zed, I couldn't go back to how slow Cursor had become
Zed is a speed demon you can't ignore.
Replit, Kilo Code, and Symbotic engineering leaders reveal how they track AI coding costs and stop runaway token spend before ...
Replimune Group, Inc. (Nasdaq: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the outcome of today's ...
The last time I spoke about Replimune Group, Inc. (REPL), it was with a Seeking Alpha article entitled "Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating." With respect to this ...
Replimune Group faces a pivotal FDA decision for RP1 in advanced melanoma, with a Sell rating reflecting approval odds and the current price. RP1 demonstrates real antitumor activity and durable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results